Ih Chang

机构：AbbVie (United States) · ORCID：0000-0002-4123-1636

发表论文 77 篇 · 总被引 8094 次 · h-index 30

代表论文

• Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2020 · New England Journal of Medicine · 被引 560)
• Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing (2019 · Neurology · 被引 198)
• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (2019 · The Lancet Neurology · 被引 189)
• Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) (2020 · Journal of Neurology Neurosurgery & Psychiatry · 被引 166)
• Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial (2022 · The Lancet · 被引 112)
• Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke (2023 · JAMA Neurology · 被引 42)